Oncology + Eternal = Oncternal

With an eternal focus on oncology, we are committed to advancing our pipeline of potential first-in-class therapies to create a new wave of better treatments for cancer. Our scientific approach harnesses the power of exciting new targets that are uniquely expressed by cancer cells — targets that offer tremendous hope to patients with critical unmet medical need.

Our Pipeline

Oncology + Eternal = Oncternal

With an eternal focus on oncology, we are committed to advancing our pipeline of potential first-in-class therapies to create a new wave of better treatments for cancer. Our scientific approach harnesses the power of exciting new targets that are uniquely expressed by cancer cells — targets that offer tremendous hope to patients with critical unmet medical need.

Our Pipeline

Oncology + Eternal = Oncternal

With an eternal focus on oncology, we are committed to advancing our pipeline of potential first-in-class therapies to create a new wave of better treatments for cancer. Our scientific approach harnesses the power of exciting new targets that are uniquely expressed by cancer cells — targets that offer tremendous hope to patients with critical unmet medical need.

Our Pipeline

Welcome to Oncternal Therapeutics

 

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. We’re committed to translate pioneering areas of cancer research into approved therapies that can be used to treat multiple cancer types.

About Our Science Meet Our Team

Latest Release

Clinical-Stage Products
for Rare Cancers

Cirmtuzumab

Humanized Monoclonal Antibody

TK216

Transcription Factor Inhibitor

We are enrolling patients:

  • With B-Cell Lymphoid Malignancies (chronic lymphocytic leukemia and mantle cell lymphoma) for a Phase 1b/2 study of cirmtuzumab in combination with ibrutinib
  • With HER2 negative, metastatic breast cancer for a Phase 1b study of cirmtuzumab in combination with paclitaxel
  • With Ewing sarcoma for a Phase 1 study of TK216, our small-molecule inhibitor of ETS-family transcription factor oncoproteins, in combination with vincristine
Participate in Our Trials